A Multi-Centre, Double-Blind , Randomized, Placebo-Controlled Phase II/III Study of Adefovir Dipivoxil for the Treatment of Chinese Patients With HBeAg Positive Chronic Hepatitis B Followed by Long-Term (5 Years Total) Adefovir Dipivoxil Treatment. (Report on Year 1 and Year 2 Data).
Phase of Trial: Phase III
Latest Information Update: 23 Apr 2013
At a glance
- Drugs Adefovir dipivoxil (Primary)
- Indications Hepatitis B
- Focus Registrational; Therapeutic Use
- Sponsors GlaxoSmithKline
- 07 Apr 2009 Trial phase changed from II/III to III as reported by ClinicalTrials.gov.
- 11 Mar 2009 New trial record